GlaxoSmithKline: assumes development of T-cell therapy
(CercleFinance.com) - GlaxoSmithKline said it has agreed with Adaptimmune on the transition to GSK of the development programme for GSK3377794, a T-cell therapy.
GSK '794 is an engineered T-cell therapy, for which a patient's own cells have been genetically modified to recognise and kill tumour cells. The two companies believe the compound could show promising results in treating sarcomas, melanoma, or gastro-intestinal cancers.
Effective immediately, GSK will assume responsibilities for all ongoing studies of the T-cells. Successful development and commercialisation would trigger additional payments to Adaptimmune.
Tomorrow GSK will announce second quarter results and give an update on R&D.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
GSK '794 is an engineered T-cell therapy, for which a patient's own cells have been genetically modified to recognise and kill tumour cells. The two companies believe the compound could show promising results in treating sarcomas, melanoma, or gastro-intestinal cancers.
Effective immediately, GSK will assume responsibilities for all ongoing studies of the T-cells. Successful development and commercialisation would trigger additional payments to Adaptimmune.
Tomorrow GSK will announce second quarter results and give an update on R&D.
Copyright (c) 2018 CercleFinance.com. All rights reserved.